Elahere approved by NICE: What does this mean for patients?
Join our free webinar to understand what this new treatment means for women with ovarian cancer
In June 2026, the National Institute for Health and Care Excellence (NICE) approved Elahere (mirvetuximab soravtansine) for use on the NHS in England for eligible women with ovarian cancer.
For many women living with platinum-resistant ovarian cancer, this marks the first major treatment breakthrough in almost 20 years.
To help explain what this decision means in practice, we're hosting a free online webinar with leading ovarian cancer specialist Dr Jon Krell, Associate Professor and Consultant Medical Oncologist at Imperial College London.
Whether you're living with ovarian cancer, supporting a loved one, or simply want to understand the latest treatment developments, everyone is welcome.
Date: Wednesday 22 July 2026
Time: 9:00am–9:30am (BST)
Location: Online
What you'll learn
During this 30-minute webinar we'll cover:
- What Elahere is and how it works
- Who is eligible for treatment
- What "folate receptor-alpha (FRα) positive" means
- The benefits shown in clinical trials
- Commonly reported side effects
- How patients can access Elahere through the NHS
- What this approval means across England, Wales, Scotland and Northern Ireland
There will also be an opportunity to submit questions in advance for Dr Krell to answer during the webinar.
Dr Jon Krell
Meet the speaker
Dr Jon Krell
Associate Professor and Consultant Medical Oncologist at Imperial College London
Dr Krell specialises in the treatment of gynaecological cancers and has extensive experience in ovarian cancer research and new treatment approaches. During the webinar, he'll explain what the NICE decision means for patients today and answer some of the most common questions about Elahere.
Why is this approval so significant?
NICE has recommended Elahere for women in England with folate receptor-alpha (FRα) positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer after one to three previous lines of systemic treatment.
This is the first new treatment approved for this group of women in nearly two decades, offering an important new option when platinum chemotherapy is no longer effective.
Marie-Claire Platt, Director of Research and Policy at Ovarian Cancer Action, said:
"Women living with platinum-resistant ovarian cancer have been left behind for too long. That changes in England today, with the first breakthrough for these women in twenty years.
We welcome this news and the precious extra time Elahere can give these women with their loved ones."
Ovarian Cancer Action's role
Ovarian Cancer Action was proud to represent the patient voice throughout the NICE appraisal process.
Following NICE's initial decision not to approve Elahere, we asked members of our community to share their experiences of living with platinum-resistant ovarian cancer.
Together, you told us:
- more treatment options are urgently needed
- additional time with loved ones is invaluable
- quality of life on chemotherapy can be incredibly difficult.
We submitted this evidence to NICE alongside patient expert testimony, helping ensure that the experiences of women and families were heard during the appraisal process.
Thank you to everyone who shared their stories. Your voices helped shape this decision.
Register for the webinar
This free online session is open to everyone.
If you're living with ovarian cancer, supporting someone who is, or simply want to understand what the approval of Elahere means, we'd love you to join us.
You'll also receive access to the recording after the event if you register.
